Roth Capital comments on Concert Pharmaceuticals (Nasdaq: CNCE) following initiation of Phase I safety study of CTP-730.Analyst Joseph Pantginis said ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE